Floyd Robert Michael
Known title: Chief Operating OfficerCIK: 0001828217
Associated companies
Transaction History
| PCSA | ▲ Buy | Grant | 10,000 | $8K | 2/9/2023 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 12,500 | — | 10/6/2022 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 4,163 | $0 | 10/6/2022 | View on chart |
| PCSA | ▼ Sell | Gift | 7,000 | $0 | 8/16/2022 | View on chart |
| PCSA | ▼ Sell | Gift | 7,000 | $0 | 3/31/2022 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 12,500 | — | 10/6/2021 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 4,663 | $0 | 10/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.